Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Significant Drop in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 121,000 shares, a drop of 17.5% from the February 28th total of 146,700 shares. Based on an average trading volume of 322,600 shares, the short-interest ratio is presently 0.4 days. Approximately 0.7% of the company’s shares are short sold.

Institutional Trading of Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI grew its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,575 shares of the company’s stock after buying an additional 35,575 shares during the quarter. National Bank of Canada FI owned approximately 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Price Performance

SNSE traded down $0.04 on Tuesday, reaching $0.35. 382,678 shares of the company traded hands, compared to its average volume of 909,077. The company has a market cap of $8.90 million, a price-to-earnings ratio of -0.30 and a beta of 0.16. The stock’s 50 day moving average price is $0.47 and its 200-day moving average price is $0.49. Sensei Biotherapeutics has a 52-week low of $0.25 and a 52-week high of $1.94.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its earnings results on Friday, March 28th. The company reported ($0.27) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.27). As a group, equities research analysts forecast that Sensei Biotherapeutics will post -1.17 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on SNSE. Oppenheimer boosted their target price on shares of Sensei Biotherapeutics from $3.50 to $4.00 and gave the company an “outperform” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Sensei Biotherapeutics in a report on Friday.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.